

Physicians' attitude and barriers towards the implementation of therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease real-life clinical practice questionnaire. (Single answers per question only unless otherwise stated)

A. PHYSICIAN-RELATED QUESTIONS:

1. Please tell us where do you work? (tick all that apply)

District General Hospital	
Tertiary Centre	
Teaching Hospital	
Private Practice	

2. Please tell us your grade:

Consultant Gastroenterologist	
Registrar (Gastroenterology)	
IBD Nurse Specialist	
Other (please specify)	

3. What is your gender?

Male	
Female	

4. What is your age?

25-34 years	
35-44 years	
45-54 years	
55-64 years	
≥65 years	

5. How many years (after your gastroenterology certification) have you been in practice?

0 (still in training)	
<1 year	
1-4 years	
5-9 years	
10-19 years	
>20 years	

6. What percentage of your patients have inflammatory bowel disease (IBD)?

<10%	
11-25%	
26-50%	
>50%	

7. How many patients with IBD do you evaluate and/or treat on average in a one-month period?
(please provide your best estimate)

<5	
5-10	
11-20	
20-30	
>30	

(If <5: Thank you for your participation. This survey refers exclusively to medical practitioners who evaluate and/or treat ≥ 5 IBD patients on average in a one month period)

8. In any given month, on average how many of your IBD patients are treated with anti-TNF therapy?
(Please provide your best estimate)

0	
1-4	
5-10	
11-20	

(If 0: Thank you for your participation. This survey refers exclusively to medical practitioners who use anti-TNF therapy to treat IBD)

B. TDM-RELATED QUESTIONS:

9. Do you check anti-TNF drug concentrations and anti-drug antibodies?

Yes	<input type="checkbox"/>
No	<input type="checkbox"/>

(If no, go to question 12)

10. In which clinical scenarios do you check anti-TNF drug concentrations to your IBD patients? (You can check more than one)

A. Secondary loss of response (patients who initially responded to anti-TNF therapy but now develop symptoms of active IBD)	<input type="checkbox"/>
B. Primary nonresponse (post-induction)	<input type="checkbox"/>
C. Re-starting anti-TNF therapy after a drug holiday	<input type="checkbox"/>
D. Proactive therapeutic drug monitoring (during maintenance therapy in patients responding to anti-TNF therapy)	<input type="checkbox"/>

11. How often do you check anti-TNF drug concentrations during maintenance therapy in patients responding to anti-TNF therapy (proactive therapeutic drug monitoring)?

Never	<input type="checkbox"/>
Every 2 months	<input type="checkbox"/>
Every 6 months	<input type="checkbox"/>
Every 12 months	<input type="checkbox"/>
Every 24 months	<input type="checkbox"/>
Other (please specify):	<input type="checkbox"/>

12. Indicate how much you agree or disagree with the following statements regarding barriers to the implementation of therapeutic drug monitoring (TDM) of anti-TNF therapy in real-life clinical practice.

Statement	Strongly Disagree	Somewhat Disagree	Neither Agree nor Disagree	Somewhat Agree	Strongly Agree
A. Test is expensive					
B. Uncertainty about availability in my Trust/practice					
C. Lack of overall knowledge of TDM					
D. Lack of knowledge on how to interpret and what to do with the results of TDM					
E. Time lag from serum sampling to results of TDM					
F. TDM is cumbersome and/or time consuming					
G. Lack of good evidence-based medicine of the usefulness of TDM in IBD					
H. Lack of clinical guidelines recommending the use of TDM					
I. Other (please specify)					

13. Which 3 of the above statements would you rate in order of importance as the biggest barriers to the implementation of therapeutic drug monitoring of anti-TNF therapy in real-life clinical practice.

1.
2.
3.

14. If all barriers were removed, would you check anti-TNF drug concentrations? (only for participants who replied no to question 9)

Yes	
No	

(If yes, go to question 16 / if no, end of the survey, thank you very much for your participation.)

15. If all barriers were removed, in which clinical scenarios would you check anti-TNF drug concentrations to your IBD patients? (you can check more than one)

Secondary loss of response (patients on anti-TNF who had responded but now develop symptoms of active IBD)	
Primary nonresponse (post-induction)	
Re-starting anti-TNF therapy after a drug holiday	
Proactive therapeutic drug monitoring (during maintenance therapy in patients responding to anti-TNF therapy)	

16. If all barriers were removed, how often would you check anti-TNF drug concentrations during maintenance therapy in patients responding to anti-TNF therapy (proactive therapeutic drug monitoring)?

Never	
Every 2 months	
Every 6 months	
Every 12 months	
Every 24 months	
Other (please specify):	

17. "Does your trust have a negotiated free TDM package provided with your anti-TNF supplier?"

Yes	
No	

End of the survey. Thank you very much for your participation.